Letters
Orphan drugs
EU regulations
BMJ 2011; 342 doi: https://doi.org/10.1136/bmj.d136 (Published 11 January 2011) Cite this as: BMJ 2011;342:d136
- Segundo Mariz, regulatory physician1,
- Jordi Llinares, head1,
- Kerstin Westermark, chairperson2
- 1Orphan Medicines Section, Human Medicines Special Areas, European Medicines Agency, London E14 4HB, UK
- 2Committee for Orphan Medicinal Products, Läkemedelsverket, Dag Hammarskjölds vägen 42, 75103 Uppsala, Sweden
- segundo.mariz{at}ema.europa.eu
Two articles on orphan drugs misunderstand the interplay between European Union and national regulations and reimbursement schemes.1 2 They imply that under EU legislation there is a monopoly for orphan drugs, a minimal requirement for clinical data before licensing, and financial benefits before approval.
Article 8 of …
Get access to this article and to all of thebmj.com for 14 days
Sign up today for a 14 day free trial
Access to the full version of this article requires a subscription
Please login, sign up for a 14 day trial, or subscribe below.
Sign in
Log in using your username and password
Log in through your institution
Free trial
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial
Subscribe
Article Access
Article access for 1 day
The PDF version can be downloaded as your personal record
* prices do not include VAT